SCHEMBL4149849

SCHEMBL4149849

O=C(NC1CCN(C(=O)O)CC1c1ccc(Cl)c(Cl)c1)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 4/20 0.48
HTR3E A5X5Y0 1/20 0.48
HTR3B O95264 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
HTR3A P46098 1/20 0.48
HTR3D Q70Z44 1/20 0.48
HTR3C Q8WXA8 1/20 0.48
TACR1 P25103 5/20 0.47
TACR2 P21452 4/20 0.47
TAC3 Q9UHF0 1/20 0.47
SPTLC2 O15270 5/20 0.46
TACR3 P29371 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
SLC6A2 P23975 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4141880 1.00 CHRNA7 (0.48) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL4153336 1.00 CHRNA7 (0.48) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL4124206 0.92 CHRNA7 (0.49) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL4157133 0.92 SSTR3 (0.49) TSHRTACR1TACR2SPTLC2TAS1R3
SCHEMBL4157136 0.92 SSTR3 (0.49) TSHRTACR1TACR2SPTLC2TAS1R3
SCHEMBL4157295 0.92 CHRNA7 (0.46) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL4141180 0.92 TACR2 (0.49) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL4157300 0.92 CHRNA7 (0.46) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL4141183 0.92 TACR2 (0.49) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL4149396 0.92 CHRNA7 (0.49) CHRNA7HTR3EHTR3BALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470816-B2 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-25 US disclosed
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof NTSR2, NTSR1, HNMT CHRNA7 539/4885HTR3E 215/4885HTR3B 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.